



SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021 .

Rs. In Lakhs

PART - I		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2021	31/03/2021	30/06/2020	31/03/2021
		Un-Audited	Un-Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)
1	Income				
	Revenue from operations	200.61	155.71	142.86	1,347.83
	Other Income	455.52	132.31	252.93	775.37
	Total income	656.13	288.02	395.79	2,123.20
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	409.74	321.77	340.67	1,528.50
	d) Finance costs	15.29	17.59	19.54	81.54
	e) Depreciation and amortisation expense	103.43	106.56	106.49	434.62
	f) Manufacturing Expenses	-	-	-	-
	g) R & D Expenses	884.01	589.96	494.73	2,517.04
	h) Other Expenses	92.95	98.35	88.82	356.99
	Total expenses	1,505.42	1,134.23	1,050.25	4,918.69
3	Profit before exceptional items & Tax (1-2)	(849.29)	(846.21)	(654.46)	(2,795.49)
4	Exceptional Items	-	-	-	-
5	Profit before Tax (3-4)	(849.29)	(846.21)	(654.46)	(2,795.49)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	4.58	(246.72)	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(849.29)	(850.79)	(407.74)	(2,263.21)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(11.79)	(13.09)	(11.35)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	4.58	3.97	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(11.79)	(8.51)	(7.38)	(30.67)
9	Total Comprehensive Income for the period (7+8)	(861.08)	(859.30)	(415.12)	(2,293.88)
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity		-	-	35,200.64
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(0.67)	(0.67)	(0.32)	(1.78)
	b) Diluted	(0.67)	(0.67)	(0.32)	(1.78)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



Rs. In Lakhs					
PART - I		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2021	31/03/2021	30/06/2020	31/03/2021
		Un-Audited	Un-Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)
1	Income				
	Revenue from operations	200.61	155.71	142.86	1,347.83
	Other Income	455.52	132.31	252.93	775.37
	Total income	656.13	288.02	395.79	2,123.20
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	505.53	417.05	413.82	1,852.75
	d) Finance costs	15.29	24.19	19.55	81.54
	e) Depreciation and amortisation expense	103.43	106.56	106.49	434.62
	f) Manufacturing Expenses	-	-	-	-
	g) R & D Expenses	3,852.23	1,795.58	1,053.67	7,102.73
	h) Other Expenses	100.50	101.30	97.91	398.96
	Total expenses	4,576.98	2,444.68	1,691.44	9,870.60
3	Profit before exceptional items , Tax (1-2)	(3,920.85)	(2,156.66)	(1,295.65)	(7,747.40)
4	Exceptional Items- (Ref Note:7)	-	-	-	-
5	Profit before Tax (3-4)	(3,920.85)	(2,156.66)	(1,295.65)	(7,747.40)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	4.58	(246.72)	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(3,920.85)	(2,161.24)	(1,048.93)	(7,215.12)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(11.79)	(13.09)	(11.35)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	4.58	3.97	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(11.79)	(8.51)	(7.38)	(30.67)
9	Total Comprehensive Income for the period (7+ 8)	(3,932.64)	(2,169.75)	(1,056.31)	(7,245.79)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	5,835.74
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(3.08)	(1.70)	(0.82)	(5.67)
	b) Diluted	(3.08)	(1.70)	(0.82)	(5.67)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 09, 2021. The results for the quarter ended June 30, 2021 has been reviewed by our statutory auditors.
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc
- 4) The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06, 2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date).
- 5) The COVID-19 did not have impact on the business and research operations, which includes our subsidiary, Suven Neurosciences, Inc.
- 6) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 7) During the year ended 31-03-2021 with the approval of members in EGM held on 20th March 2021, the board has issued 1,81,00,000 share warrants to promoter group on a preferential basis @ ₹ 81.57 per warrant and received 25% of issue price amounting to ₹ 3,692.00 lakhs on 26-03-2021 in accordance with SEBI Regulations and as on 2nd April 2021 share warrants have been allotted to the promoter group.
- 8) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in buildings was damaged. The company has written off net book value of assets aggregating Rs.2.28 Crores and during the current quarter ended 30th June 2021 the company has received adhoc payment of Rs.6.00 Crores from the Insurance company.
- 9) The code on social security, 2020 (Code) relating to employee benefits during employment and post employment benefits received presidential assent in september 2020. The Code has been published in Gazette of India. However, the date on which code will come into effect has not been notified. The company will assess the impact of the code when it comes into effect and will record any related impact in the relevant period when the code becomes effective.
- 10) The corresponding previous period figures have been regrouped / reclassified where ever necessary

Place : Hyderabad
Date : August 9, 2021



For SUVEN LIFE SCIENCES LTD

Venkata Jasti
VENKAT JASTI
Chairman & CEO
DIN: 00278028